US 7,320,788 B2
Enzyme treatment of foodstuffs for Celiac Sprue
Lu Shan, Stanford, Calif. (US); Michael Bethune, Stanford, Calif. (US); Chaitan Khosla, Palo Alto, Calif. (US); Jonathan Gass, Stanford, Calif. (US); Gail G. Pyle, Stanford, Calif. (US); and Gary Gray, Stanford, Calif. (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Palo Alto, Calif. (US); and Celiac Sprue Research Foundation, Palo Alto, Calif. (US)
Filed on Oct. 19, 2004, as Appl. No. 10/969,314.
Application 10/969314 is a continuation in part of application No. 10/367405, filed on Feb. 14, 2003.
Application 10/969314 is a continuation in part of application No. 10/969314.
Claims priority of provisional application 60/565668, filed on Apr. 26, 2004.
Claims priority of provisional application 60/435881, filed on Dec. 20, 2002.
Claims priority of provisional application 60/428033, filed on Nov. 20, 2002.
Claims priority of provisional application 60/422933, filed on Oct. 31, 2002.
Claims priority of provisional application 60/392782, filed on Jun. 28, 2002.
Claims priority of provisional application 60/380761, filed on May 14, 2002.
Claims priority of provisional application 60/357238, filed on Feb. 14, 2002.
Prior Publication US 2005/0249719 A1, Nov. 10, 2005
Int. Cl. A61K 38/46 (2006.01); A61K 36/00 (2006.01)
U.S. Cl. 424—94.6  [530/374; 514/2] 32 Claims
 
1. A method of treating Celiac Sprue and/or dermatitis herpetiformis in a patient suffering therefrom, the method comprising:
orally administering to said patient when consuming a gluten-containing foodstuff an effective dose 0.01 mg to 500 mg/kg body weight per day of a glutenase;
wherein said glutenase is a mixture of proteases comprising a glutamine endoprotease and a prolyl endopeptidase that attenuates gluten toxicity in said patient.